Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612861 | 0.97 | GHSR (0.50) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612824 | 0.89 | GHSR (0.50) | GHSR | |
| SCHEMBL13612840 | 0.88 | GHSR (0.54) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612845 | 0.88 | GHSR (0.56) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612859 | 0.86 | GHSR (0.51) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612847 | 0.86 | GHSR (0.53) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612838 | 0.85 | GHSR (0.70) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612770 | 0.84 | GHSR (0.57) | GHSR | |
| SCHEMBL13612863 | 0.83 | GHSR (0.66) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13612843 | 0.81 | GHSR (0.70) | GHSRCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275648-A1 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 3570/4885CYP2D6 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.